Olomorasib

N/A

Report date: 2026/04/08 16:01:24
NME

Base Information

Drug NameOlomorasib
Drug Alias NameLY-3537982KRAS-G12C-II
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursRenal InsufficiencyHepatic Insufficiency +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyLoxo Oncology IncJanssen Research & Development Llc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursRenal InsufficiencyHepatic Insufficiency +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG